3254 results about "Nucleic acid molecule" patented technology

Localized detection of RNA in a tissue sample that includes cells is accomplished on an array. The array include a number of features on a substrate. Each feature includes a different capture probe immobilized such that the capture probe has a free 3′ end. Each feature occupies a distinct position on the array and has an area of less than about 1 mm2. Each capture probe is a nucleic acid molecule, which includes a positional domain including a nucleotide sequence unique to a particular feature, and a capture domain including a nucleotide sequence complementary to the RNA to be detected. The capture domain can be at a position 3′ of the positional domain.

Localized detection of RNA in a tissue sample that includes cells is accomplished on an array. The array include a number of features on a substrate. Each feature includes a different capture probe immobilized such that the capture probe has a free 3′ end. Each feature occupies a distinct position on the array and has an area of less than about 1 mm2. Each capture probe is a nucleic acid molecule, which includes a positional domain including a nucleotide sequence unique to a particular feature, and a capture domain including a nucleotide sequence complementary to the RNA to be detected. The capture domain can be at a position 3′ of the positional domain.

Provided herein are systems and methods for analyzing biomolecules (e.g., nucleic acid molecules, proteins). A method of nucleic acid analysis can comprise: (a) providing a sample comprising a cell comprising a target polynucleotide comprising a first exon segment and a second exon segment, wherein the first exon segment and the second exon segment flank opposite ends of a splice junction site of the target polynucleotide. The method can further comprise (b) contacting the cell with: (i) a first probe, wherein the first probe hybridizes to a first target sequence of the first exon segment, and (ii) a second probe, wherein the second probe hybridizes to a second target sequence of the second exon segment. The method can further comprise (c) linking the first probe and the second probe together, thereby generating a probe-linked nucleic acid molecule comprising the first probe and the second probe. The method can further comprise (d) identifying a sequence of the probe-linked nucleic acid molecule or derivative thereof, thereby locating the splice junction site of the target polynucleotide.

The present disclosure provides humanized antibodies and antigen binding domains thereof that bind CD8α and other antibody formats comprising these antigen binding domains, their use as a targeting moiety on lipid nanoparticles (tLNP) to deliver a therapeutic payload (such as a nucleic acid molecule) or other types of payloads. The present disclosure further relates to pharmaceutical compositions comprising the humanized anti-CD8α antibodies and CD8-targeted tLNP encapsulating a payload.

The invention provides an artificial nucleic acid molecule which is used for improving the expression quantity of target amino acid, polypeptide or protein. The artificial nucleic acid molecule at least comprises a target 5'untranslated region (UTR), a target coding region (CDS) and a target 3 'untranslated region (UTR). Wherein the sequence of the target 5 'UTR is one of the following sequences: 5' UTR of a high-expression gene and a 5 'UTR variant of the high-expression gene. The sequence of the target 3 'UTR is one of the following sequences: 3' UTR of a high-expression gene and a 3 'UTR variant of the high-expression gene. Optionally, the artificial nucleic acid molecule may further comprise, for example, a 5 '-end cap structure (Cap), a PolyA tail. The 5 'UTR and the 3' UTR have regulating effects on translation and stability of nucleic acid molecules, so that the 5 'UTR, the 3' UTR and variants thereof are selected from high-expression genes, the nucleic acid molecules can be further stabilized and are not easy to degrade, and the amount of protein or polypeptide obtained by translation of the nucleic acid molecules can be increased. The invention also provides methods for making, delivering, and using such artificial nucleic acid molecules, as well as the use of the artificial nucleic acid molecules for the treatment and / or prevention of related diseases or disorders.

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

The present disclosure provides methods for reducing sequencing errors comprising one or any combination of: (i) removing deaminated bases in any nucleic acid molecule throughout a library preparation workflow which includes immobilised splints which bind to the library, the use of a compaction oligonucleotide, optionally with an intervening sequence, formation of closed circular nucleic acids, creating gaps using glycosylase and lyase activities at positions with deaminated bases. The library may be sequenced using pairwise sequencing, e.g. with dark sequencing and / or sequencing using a multivalent labelled probe for the formation of an avidity molecule and soluble primer and polymerase. Method for sequencing concatemers in which the concatermers are contacted with polymerases, soluble primers and a multivalent labelled molecule which forms a complex with the polymerase. Detecting polymerase position and nucleobase bound to the polymerase in the complex. These methods generate higher quality base calls during downstream sequencing workflows.

The invention belongs to the field of gene engineering, and relates to a DNA binding protein based on TraC effect protein, a fusion protein with a cytosine / adenine base editing function, an editing system and nucleic acid molecules or constructs for encoding the DNA binding protein and the fusion protein. The invention also relates to complexes and kits for gene editing comprising the fusion proteins of the invention or the nucleic acid molecules encoding them. The base editing tool disclosed by the invention can realize efficient, accurate and safe base editing in cells of various eukaryotes such as animals and plants. The unique characteristics of the base editing tool enrich the types of existing base editing tools, and the base editing tool has wide application prospects.

The invention discloses a self-replicating RNA (Ribonucleic Acid) molecule, a porcine rotavirus RNA vaccine and application thereof, and relates to the technical field of vaccines. According to the present invention, the coding sequence of the porcine rotavirus G9P23 type VP4 protein is optimized, such that the fact that the saRNA prepared by using the nucleotide sequence represented by the SEQ ID NO: 10 can secrete the high porcine rotavirus G9P23 type VP4 protein antigen after the cell transfection is found; after the optimized porcine rotavirus G9P23 type VP4 protein is used for immunizing experimental animals, the level of neutralizing antibodies generated by the animals can be improved, and the challenge protection effect is enhanced. Therefore, the nucleic acid molecule provided by the invention can be used for developing drugs and vaccines for causing protective immune response in experimental animal bodies. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a good application prospect.

A nucleic acid molecule comprising: i) a first nucleic acid comprising a double stranded inhibitory ribonucleic acid (RNA) molecule comprising a sense and an antisense strand designed with reference to a nucleotide sequence comprising a cardiovascular disease associated gene to be silenced and wherein said cardiovascular gene is proprotein convertase subtilisin kexin 9 (PCSK9) there is provided a single stranded deoxyribonucleic acid (DNA) molecule conjugated to the 5’ end of said sense strand; and ii) a second nucleic acid comprising a double stranded inhibitory ribonucleic acid (RNA) molecule comprising a sense and an antisense strand designed with reference to a different cardiovascular disease associated gene to be silenced wherein said cardiovascular gene is lipoprotein (a) (Lp(a)) and wherein there is provided a single stranded deoxyribonucleic acid (DNA) molecule conjugated to the 5’ end of said sense strand wherein the single stranded deoxyribonucleic acid (DNA) molecule is substantially complementary to the single stranded deoxyribonucleic acid (DNA) molecule set forth in i) above and anneals by complementary base pairing to form a double stranded DNA linker that links the first and second double stranded inhibitory ribonucleic acid (RNA) molecules.

The invention relates to the technical field of biological medicine, in particular to a T cell receptor targeting AFP peptide, a preparation method of the T cell receptor and a companion diagnostic kit. A T cell receptor targeting an AFP peptide is provided, the sequence of the AFP peptide is FMNKFIYEI, and the T cell receptor comprises a TCR [alpha] chain variable domain and a TCR [beta] chain variable domain. Corresponding nucleic acid molecules, vectors and host cells, and methods of making T cell receptors are provided. Further provided is a companion diagnostic kit containing the cell receptor. The invention provides a better choice for concomitant diagnosis and treatment products of cells of alpha fetoprotein (AFP).

The present invention relates to a nucleic acid molecule inhibiting factor 11 (FXI) gene expression in a cell by means of RNAi, comprising a sense sequence and an antisense sequence complementary to each other, or consisting of a sense sequence and an antisense sequence complementary to each other. The FXI inhibition rate of the nucleic acid molecule is significantly superior to that of other small nucleic acid molecules which inhibit the expression of FXI by means of RNAi.

Provided by the present invention are a bispecific T-cell engager, recombinant oncolytic virus thereof, and use thereof. The present invention provides an αCD47 and αCD3 bispecific T-cell engager. The present invention also provides an isolated nucleic acid molecule that encodes said bispecific T-cell engager. The present invention also provides an expression framework of said bispecific T-cell engager BiTE. The present invention also provides a recombinant oncolytic virus, and said oncolytic virus is operably inserted with or contains the expression framework of said bispecific T-cell engager BiTE. In the present invention, the bispecific T-cell engager is combined with the oncolytic virus, and in comparison with pure gene therapy or virotherapy, the oncolytic virus significantly enhances the inhibition capability on malignant tumors.

The invention relates to the field of plant gene map-based cloning and molecular breeding. Specifically, the invention provides a nucleic acid molecule and a polypeptide, and also provides a recombinant vector, a host cell and a plant or a part, a seed, a cell or a progeny thereof containing the nucleic acid molecule. Furthermore, the invention also provides a method for preparing the transgenic plant, and a method for regulating and controlling the nitrogen utilization efficiency, nitrate absorption or transport, biomass and / or yield of the plant.

The present disclosure provides multivalent molecules (e.g., compositions of Formula (I), an ionized form thereof, an isomer thereof, or a salt thereof. The present disclosure further provides methods for the use of the compositions, e.g. in the sequencing of poly-nucleic acid molecules.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

The present disclosure relates in some aspects to methods, systems, and kits for sequencing a template nucleic acid molecule, where the methods comprise: (i) contacting a priming strand bound to the template nucleic acid molecule with a first plurality of nucleotide molecules and a polymerase coupled to a heterologous polynucleotide-binding moiety to form a complex comprising a 3′ terminus of the priming strand, the template nucleic acid molecule, the polymerase, and a nucleotide molecule of the first plurality of nucleotide molecules, wherein the polynucleotide-binding moiety enhances stability of the complex, and wherein the priming strand comprises a reversibly-terminated nucleotide at its 3′ end such that the nucleotide molecule of the transient complex is not incorporated; and (ii) detecting a presence of the nucleotide molecule in the complex to identify a complementary nucleotide in the template nucleic acid molecule.

Disclosed are compositions comprising a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence or portion thereof of a target ribonucleic acid (RNA) sequence. The nucleic acid molecule may further encode one or more stabilization domains. The one or more stabilization domains may be configured to reduce a cellular nuclease activity compared to a nucleic acid molecule that does not comprise the one or more stabilization domains.

The present invention provides an ATP phosphoribosyltransferase mutant and its application in histidine production. The mutant is obtained by performing point mutations at positions 84 and / or 205 on the amino acid sequence of the wild-type ATP phosphoribosyltransferase derived from Acinetobacter baumannii. The mutant, the nucleic acid molecule encoding the mutant, the expression cassette containing the nucleic acid molecule, the recombinant vector or the recombinant microorganism are used for the production of L-histidine, and the yield of L-histidine is significantly increased, laying a good foundation for the large-scale industrial production of L-histidine.

The invention relates to the technical field of gene isolation and plant improvement, in particular to a late blight resistance gene, a biological material and application. The Rpi-card1 nucleic acid molecule provided by the invention comprises a nucleotide sequence as shown in any one of SEQ ID NO: 1-4; a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 5 or 6; the nucleotide sequence has at least 75% sequence identity with the nucleotide sequence. The invention provides an important gene resource for potato late blight resistance breeding, overcomes the problem of disease resistance loss of potato varieties, and provides a new guarantee for lasting disease resistance of potatoes.

The present invention belongs to the field of biology, and relates to a nucleic acid molecule encoding an anti-NKG2A antibody, a recombinant vector comprising the nucleic acid molecule, and an expression method wherein the nucleic acid molecule comprises codons optimized for expression cells. By utilizing the nucleic acid molecule disclosed by the invention, the expression quantity of the anti-NKG2A antibody in cells can be increased, the yield of the anti-NKG2A antibody is increased, and the production cost is reduced.

The present disclosure relates in some aspects to methods, systems, and kits for sequencing a template nucleic acid molecule using nucleotide-fluorophore complexes. In some embodiments, each nucleotide-fluorophore complex comprises: (i) a single nucleotide attached to a core; and (ii) a plurality of fluorophores attached to the core; wherein each nucleotide-fluorophore complex comprises no more than one nucleotide. In some embodiments, the methods provided herein achieve improved signal intensity and sensitivity.

The invention belongs to the technical field of colloidal gold immunochromatography, and relates to a cetirizine monoclonal antibody, a nucleic acid molecule, a carrier, a detection kit and application thereof. The cetirizine monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a VH-CDR1, a VH-CDR2 and a VH-CDR3, the light chain variable region comprises a VL-CDR1, a VL-CDR2 and a VL-CDR3, the sequence of the VH-CDR1 is as shown in SEQ ID NO.1, the sequence of the VH-CDR2 is as shown in SEQ ID NO.2, and the sequence of the VH-CDR3 is as shown in SEQ ID NO.3. The invention further discloses a preparation method of the cetirizine monoclonal antibody. The monoclonal antibody provided by the invention has high sensitivity to cetirizine, the lowest detection limit is 0.007 ng / mL, the quantitative range is 0.017-0.282 ng / mL, and the specificity is strong.

The invention discloses a gene for improving wheat immature embryo transformation efficiency and application thereof, and belongs to the technical field of plant genetic engineering. According to the invention, a new wheat regeneration gene TaDJA gene is found, and the TaDJA gene is over-expressed in a wheat variety 'Kefeng No.3' which is extremely difficult to transform, so that the callus induction rate and the transformation efficiency of wheat immature embryos can be improved; the method is beneficial for integrating exogenous nucleic acid molecules into the genome of the wheat variety difficult to transform, and provides technical support for genetic improvement of the wheat variety difficult to transform.

The present disclosure relates to isolated nucleic acid molecules comprising at least two double-stranded inhibitory ribonucleic acid (RNA) molecules adapted to silence the same or different genes by RNA interference to enhance silence, thereby modulating gene expression.

Aspects of the disclosure relate to methods for treating disorders such as cutaneous squamous cell carcinoma (cSCC) in a subject having a tumor by intratumoral administration of chemically-modified double stranded nucleic acid molecules directed against a gene encoding PD- 1.

The present disclose provides a method for classifying a sample derived from a subject. The method may comprise obtaining a sample comprising nucleic acid molecules from the subject. The method can comprise assaying the nucleic acid molecules to generate a data set comprising methylation states of one or more genomic regions. The one or more genomic regions can comprise differentially methylation regions (DMRs). The method can comprise processing at least a portion of the data set to generate an output indicative of cancer in the subject. The portion of the data set can pertain to a set of DMRs specific to the subject.

Provided is a method for using a multi-epitope antigen to construct an RNA vaccine for feline infectious peritonitis virus (FIPV). The method relates to an isolated nucleic acid molecule. The nucleic acid molecule comprises: at least one of a first nucleic acid fragment, a second nucleic acid fragment, a third nucleic acid fragment, a fourth nucleic acid fragment and a fifth nucleic acid fragment, wherein the first nucleic acid fragment is derived from the N-terminal domain (NTD) of the N protein of the FIPV strain QS, the second nucleic acid fragment is derived from the C-terminal domain (CTD) of the N protein from the FIPV strain QS, the third nucleic acid fragment encodes the NSP12 protein of the FIPV strain QS, the fourth nucleic acid fragment is derived from the epitope HR2_4 of the S protein of the FIPV strain 79-1146, the fifth nucleic acid fragment is derived from the epitope HR2_11 of the S protein of the FIPV strain 79-1146, and the nucleic acid molecule is RNA.

The present application discloses an antibody binding to a tumor necrosis factor-like ligand 1A (TL1A), a nucleic acid molecule encoding the antibody, a vector comprising the nucleic acid molecule, a host cell comprising the nucleic acid molecule or the vector, a method for preparing and purifying the antibody, and a use of the antibody.

The present invention relates to a nucleic acid molecule for inhibiting FXI gene expression through RNAi, and more particularly, to a nucleic acid molecule for inhibiting FXI gene expression through RNAi, the nucleic acid molecule comprises a sense sequence and an antisense sequence which are complementary to each other or is composed of a sense sequence and an antisense sequence which are complementary to each other, and the FXI inhibition rate of the nucleic acid molecule is significantly superior to that of other small nucleic acid molecules for inhibiting FXI expression through RNAi.